Myeloproliferative disorder characterized by Philadelphia chromosome (BCR-ABL fusion gene) causing overproduction of myeloid cells. Three phases: chronic (most common at diagnosis), accelerated, and blast crisis. Treatment with tyrosine kinase inhibitors has dramatically improved prognosis. Symptoms include fatigue, weight loss, splenomegaly, and sometimes bleeding or infections.
Requiring peripheral blood or bone marrow stem cell transplant, or continuous myelosuppressive/immunosuppressive therapy (100% for 6 months post-transplant/treatment, then re-evaluate)
Requiring intermittent myelosuppressive therapy, molecularly targeted therapy with tyrosine kinase inhibitors, or interferon when not in apparent remission
In apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors
Medical Evidence
Current diagnosis from a qualified healthcare provider, medical records documenting symptoms and treatment history
Service Connection
Evidence linking your condition to military service (service treatment records, incident reports, or nexus letter)
Personal Statement
Your detailed account of how chronic myelogenous leukemia (cml) affects your daily life and when symptoms began
Lay Evidence
Buddy letters from fellow service members or family who can corroborate your symptoms
During your Compensation & Pension exam for chronic myelogenous leukemia (cml), examiners will assess your symptoms against the rating criteria above.
Be specific: Describe your worst day, not your average day
Document everything: Bring copies of all medical records and evidence
Functional impact: Explain how symptoms affect work, sleep, and daily activities
VA Claims Assistant
Hey! I'm Scout, your VA claims assistant. I can help with questions about conditions, ratings, secondary connections, C&P exams, and more. What can I help you with?
Powered by ClaimDuty AI · Not legal or medical advice